Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Heiko Babel
Observed name:
Babel, Heiko
Institutions:
AbbVie (United States),
AbbVie (Germany)
Observed institutions:
Technische Hochschule Mannheim,
Boehringer Ingelheim (Germany),
Helmholtz Centre for Environmental Research,
Heidelberg University,
AbbVie (United States),
AbbVie (Germany),
Max Planck Institute for Terrestrial Microbiology
show all 7
ORCID:
0000-0002-8901-7882
Observed ORCID:
0000-0002-8901-7882
OpenAlex ID:
A5026418411
Evolutionary engineering of E. coli MG1655 for tolerance against isoprenol
2020
·
Heiko Babel
, Jens O. Krömer
·
Biotechnology for Biofuels
·
25
PDF
Ratiometric population sensing by a pump-probe signaling system in Bacillus subtilis
2020
·
Heiko Babel
, Pablo Naranjo-Meneses
, et al.
·
Nature Communications
·
24
PDF
About Model Validation in Bioprocessing
2021
·
Vignesh Rajamanickam
, Heiko Babel
, et al.
·
Processes
·
6
PDF
Molecular and cellular factors control signal transduction via switchable allosteric modulator proteins (SAMPs)
2016
·
Heiko Babel
, Ilka B. Bischofs
·
BMC Systems Biology
·
6
PDF
Population Pharmacokinetics and Exposure‐Response Analyses for Telisotuzumab Vedotin in Patients With c‐Met Protein Overexpressing Tumors
2026
·
Heiko Babel
, Priya Brunsdon
, et al.
·
CPT Pharmacometrics & Systems Pharmacology
·
2
Reducing Structural Nonidentifiabilities in Upstream Bioprocess Models Using Profile‐Likelihood
2025
·
Heiko Babel
, Ola Omar
, et al.
·
Biotechnology and Bioengineering
·
2
PDF
Dose optimization and exposure-response analyses to support optimal dose of ABBV-400, a novel C-met–targeting antibody drug conjugate, in patients with metastatic colorectal cancer (mCRC).
2024
·
Carla Biesdorf de Almeida
, Benjamin Engelhardt
, et al.
·
Journal of Clinical Oncology
·
1
PDF
A Laboratory Experiment for Teaching Bioprocess Control Part 1: Hardware Setting
2012
·
Martin J. Wolf
, Vasil Ninov
, et al.
·
IFAC Proceedings Volumes
·
1
Population Pharmacokinetics and Exposure‐Response Analyses for Ubrogepant Efficacy and Safety in the Acute Treatment of Migraine: Analysis of Phase 1–3 Studies
2026
·
Sven Stodtmann
, Lucia Siovitz
, et al.
·
The Journal of Clinical Pharmacology
Exposure-response analyses from a randomized dose optimization study of telisotuzumab adizutecan (Temab-A) in combination with bevacizumab in patients with metastatic colorectal cancer (mCRC).
2026
·
Mohammad Alshaer
, Heiko Babel
, et al.
·
Journal of Clinical Oncology
Restarting etentamig therapy after dosing delays or interruptions: Population pharmacokinetics (PopPK) and PK/PD simulations and supporting clinical data
2025
·
Sneha Rathi
, Vanessa Schmitt
, et al.
·
Blood
Exposure-Response (ER) and Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Optimal Step-up Dose (SUD) Selection to Improve Cytokine Release Syndrome (CRS) Safety Profile of Abbv-383 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
2024
·
Fan Wang
, Heiko Babel
, et al.
·
Blood
Combined multi-analyte population PK modeling of ABBV-400, a novel c-Met targeting ADC
2024
·
Heiko Babel
, Carla Biesdorf de Almeida
, et al.
Model for FRET sensors of allosteric switchable modulator proteins for the determination of allosteric parameters
2022
·
Heiko Babel
·
bioRxiv (Cold Spring Harbor Laboratory)
PDF
Additional file 1: of Molecular and cellular factors control signal transduction via switchable allosteric modulator proteins (SAMPs)
2016
·
Babel, Heiko
, Bischofs, Ilka
·
Figshare
Show more works
View as search
Works count:
17
Citation count:
67
H-index:
4
I10-index:
2
Year
Topic
Type
